Profile for Australia Patent: 2020227021
✉ Email this page to a colleague
US Patent Family Members and Approved Drugs for Australia Patent: 2020227021
| US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
|---|---|---|---|---|
| 10,111,839 | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| 10,292,938 | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| 10,292,939 | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| 10,449,159 | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| 10,500,162 | Oct 30, 2035 | Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride |
| >US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |
